Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04397757 · ClinicalTrials.gov registry record · Phase 1
COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.
A Phase 1 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
NCT04397757: Completed Phase 1 study, sponsored by University of Pennsylvania.
NCT04397757 is a Phase 1 study that has completed, run by University of Pennsylvania. The registered enrollment target is 80 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04397757, a Phase 1 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
The purpose of this study is to see if this plasma can be safely used in humans with COVID-19 and to see if it improves patients' health as compared to not using it in patients with pneumonia caused by SARS-CoV-2.
Interventions
- BIOLOGICAL COVID-19 Convalescent Plasma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2020-05-13 |
| Est. Completion | 2021-03-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04397757
The ClinicalTrials.gov registry entry for NCT04397757 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which COVID-19 Convalescent Plasma is the first listed.
NCT04397757 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04397757 about?
NCT04397757 is a clinical study titled "COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.". The purpose of this study is to see if this plasma can be safely used in humans with COVID-19 and to see if it improves patients' health as compared to not using it in patients with pneumonia caused by SARS-CoV-2.
What is the current status of trial NCT04397757?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2020-05-13. Estimated completion is 2021-03-08.
What interventions are being tested in trial NCT04397757?
The interventions under investigation include: COVID-19 Convalescent Plasma (BIOLOGICAL).
Who is sponsoring clinical trial NCT04397757?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.